Browse articles from EyeWorld.org related to glaucoma. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
➤ FDA approves new EDOF with limited dysphotopsias ➤ Phase 1/2 12-month data for IOL-based drug delivery system ➤ Topline results from Phase 2a wet AMD study ➤ FDA grants Breakthrough Device Designation to brain implant technology ➤ FDA allows Phase 1/2 trial to begin for investigational cell therapy for familial drusen ➤ ASCRS news and events
➤ Positive results in Phase 3 superiority trial for wet AMD treatment ➤ Dosing begins for first-in-human myopia prevention drop ➤ Pre-NDA meeting with FDA for IOP-lowering drop ➤ Company news ➤ ASCRS news and events
➤ New drop for temporary presbyopia relief approved ➤ First-in-human results for accommodating IOL ➤ Enrollment complete in Phase 2/3 trial for Stargardt therapy ➤ Type C meeting completed with FDA to advance urcosimod for neuropathic corneal pain ➤ Company news ➤ ASCRS news and events
➤ Study: low-dose pilocarpine reduces pupil diameter without significant ciliary muscle response ➤ First patient receives investigational surgical system for glaucoma ➤ Clinical program for RP gene therapy begins ➤ FDA approves IND for steroid-free, topical anti-inflammatory ➤ Compassionate use approved for investigational drug intended for neuropathic corneal pain ➤ Company news ➤ ASCRS news and events
➤ Enrollment complete in first-in-human trial evaluating treatment for patients with Usher syndrome ➤ First patients randomized in drug-eluting IOL trial ➤ Preliminary data from Phase 2 gene modifier study for geographic atrophy ➤ ASCRS news and events
➤ FDA accepts BLA for thyroid eye treatment ➤ Breakthrough Therapy Designation granted to investigational neuroprotective for optic neuropathies ➤ FDA issues complete response letter for wet AMD BLA resubmission ➤ Biosimilar approved for retinal therapies ➤ FDA approves IND for corneal genome editing program ➤ Study: ‘largest prospective trial ever’ on postcataract endophthalmitis prophylaxis ➤ Complimentary access to video journal ➤ Company news ➤ ASCRS news and events
➤ FDA review extended for dry eye disease treatment ➤ Key data gathered for expected NDA submission ➤ Phase 2b results for GA treatment ➤ Phase 3 studies discontinued for thyroid eye disease ➤ ASCRS news and events
In his introduction to the Glaucoma section, Manjool Shah, MD, reflected on two evolutions explored in this issue: the expansion of surgical techniques and the critical recognition of the complete, human dimension of patient care.
For patients, vision loss can feel like the closing of a door to independence. Ophthalmologists often stand at the threshold of this life-altering moment, particularly when caring for patients with degenerative conditions such as glaucoma. Opening the door to mental healthcare unlocks an important dimension of support.
➤ FDA approves treatment for macular edema following RVO ➤ New cyclosporine product receives approval for dry eye ➤ First human implant of 3D-bioprinted cornea ➤ Topline results from Phase 3 trial for Stargardt disease ➤ First patient treated with IDE glaucoma therapy ➤ Enrollment complete for Phase 2 trial for geographic atrophy treatment ➤ First patient implanted with investigational glaucoma shunt in trial ➤ Positive review of Phase 3 pivotal trial for AMD ➤ Company news ➤ ASCRS news and events
Get the latest ophthalmology news delivered to your inbox every Friday.